Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Sequential administration of cytokine genes to enhance cellular immune responses and CD4 (+) T memory cells during DNA vaccination.

Su B, Wang J, Zhao G, Wang X, Li J, Wang B.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1659-67. doi: 10.4161/hv.22105. Epub 2012 Nov 1.

2.

The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination.

Su B, Wang J, Wang X, Jin H, Zhao G, Ding Z, Kang Y, Wang B.

Vaccine. 2008 Sep 19;26(40):5111-22. doi: 10.1016/j.vaccine.2008.03.089. Epub 2008 Apr 21.

PMID:
18462845
3.

Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus.

Wang X, Zhang X, Kang Y, Jin H, Du X, Zhao G, Yu Y, Li J, Su B, Huang C, Wang B.

Vaccine. 2008 Sep 19;26(40):5135-44. doi: 10.1016/j.vaccine.2008.03.088. Epub 2008 May 6.

PMID:
18462848
4.

Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help.

Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB.

J Immunol. 2005 Jul 1;175(1):112-23.

5.

Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii.

Chen J, Li ZY, Petersen E, Liu WG, Zhu XQ.

Exp Parasitol. 2016 Mar;162:18-23. doi: 10.1016/j.exppara.2015.12.013. Epub 2015 Dec 17.

PMID:
26706605
6.
7.

Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice.

Chen J, Li ZY, Huang SY, Petersen E, Song HQ, Zhou DH, Zhu XQ.

BMC Infect Dis. 2014 Sep 6;14:487. doi: 10.1186/1471-2334-14-487.

8.

Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct.

Zou Q, Wu B, He X, Zhang Y, Kang Y, Jin J, Xu H, Liu H, Wang B.

J Biomed Biotechnol. 2010;2010:562356. doi: 10.1155/2010/562356. Epub 2010 Apr 27.

9.

Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.

Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, Schadeck EB, Boyer JD, Pavlakis GN, Weiner DB, Sidhu M, Eldridge JH, Israel ZR.

Vaccine. 2007 Jun 21;25(26):4967-82. Epub 2007 Feb 14.

PMID:
17335943
10.

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.

Clin Vaccine Immunol. 2010 May;17(5):793-801. doi: 10.1128/CVI.00006-10. Epub 2010 Mar 31.

11.

Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.

Li W, Li S, Hu Y, Tang B, Cui L, He W.

Vaccine. 2008 Jun 19;26(26):3282-90. doi: 10.1016/j.vaccine.2008.03.081. Epub 2008 Apr 18.

PMID:
18472194
12.

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, McMahon-Pratt D.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1204. doi: 10.1371/journal.pntd.0001204. Epub 2011 Jun 14.

13.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
14.
15.

Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.

Cui FD, Asada H, Jin ML, Kishida T, Shin-Ya M, Nakaya T, Kita M, Ishii M, Iwai M, Okanoue T, Imanishi J, Mazda O.

Gene Ther. 2005 Jan;12(2):160-8.

PMID:
15470476
16.

Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge.

Wang G, Pan L, Zhang Y, Wang Y, Zhang Z, Lü J, Zhou P, Fang Y, Jiang S.

PLoS One. 2011;6(11):e27605. doi: 10.1371/journal.pone.0027605. Epub 2011 Nov 15.

17.

CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.

Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, Shin YK, Lee WJ, Park YM, Kim D.

J Immunother. 2010 Jun;33(5):510-22. doi: 10.1097/CJI.0b013e3181d75cef.

PMID:
20463596
18.

SIV antigen-specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL-12.

Lindsay RW, Ouellette I, Arendt HE, Martinez J, DeStefano J, Lopez M, Pavlakis GN, Chiuchiolo MJ, Parks CL, King CR.

Vaccine. 2013 Oct 1;31(42):4749-58. doi: 10.1016/j.vaccine.2013.08.011. Epub 2013 Aug 14.

19.

A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses.

Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Postól E, Kalil J, Cunha-Neto E.

PLoS One. 2011 Feb 11;6(2):e16921. doi: 10.1371/journal.pone.0016921.

Supplemental Content

Support Center